TITLE:
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

CONDITION:
Macular Degeneration

INTERVENTION:
Anecortave Acetate 15 mg sterile suspension

SUMMARY:

      The purpose of this study is to demonstrate that Anecortave Acetate is as effective after
      twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible
      for initial PDT treatment for wet age-related macular degeneration.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 50 Years to N/A
Criteria:

        Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV
        due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to
        20/400 (Snellen equivalent) in the study eye. Clinically relevant concomitant diseases
        will be excluded.
      
